Naslov
BPC 157 given during reperfusion counteracts portal hypertension, caval hypertension and aortal hypotension in rats used to have portal triad obstruction (Pringle maneuver)

Autori
Kolovrat, Marijan ; Gojković, Slaven ; Krezić, Ivan ; Malekinušić, Dominik ; Drmić, Domagoj ; Horvat, Katarina ; Đuzel, Antonija ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gastroenterology (New York, N.Y. 1943), 156 (2019), 6(S) / - , 2019, S-564

Skup
Digestive Disease Week

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 18.05.2019. - 21.05.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
portal triad obstruction ; reperfusion ; BPC 157

Sažetak
Aim. Reperfusion provokes major disturbances after Pringle maneuver. We revealed the stable gastric pentadecapeptide BPC 157 as the therapy of the hemodynamic disturbances after Pringle maneuver, temporary portal triad obstruction (PTO) (hepatic artery, portal vein, common bile duct occlusion for 30 min), BPC 157 given during reperfusion, in the post-PTO period. Previously, we noted in rats with PTO that BPC 157 may beneficially increase vessels branching in intestinal serosa and counteract intestinal lesions, counteract free radicals formation and most importantly, counteract portal hypertension and caval hypotension (Gastroenterology, 2017, Vol. 152, Issue 5, S909–S910 ; Gastroenterology, 2015, Vol. 148, Issue 4, S-650, Gastroenterology, 2015, Vol. 148, Issue 4, S-548). Methods: In deeply anesthetized and laparatomized rats that used to have PTO, the recording lasted 5 minutes with a cannula (BD Neoflon™ Cannula) (assessed in one minute intervals) connected to a pressure transducer (78534C MONITOR/ TERMINAL Hewlett Packard), inserted into the portal vein, inferior caval vein and abdominal aorta at the level of bifurcation at 24 h of reperfusion time. Medication (BPC 157 (10 μg/kg, 10 ng/kg), or saline (5 ml/kg) (controls)) was applied as an abdominal bath in rats used to have PTO, in post- PTO-period, at 1 min or at 24 h reperfusion time. Results: Continuous assessment of portal, caval and aortal pressure at the end of the PTO-period, PTO removal, and the immediate period thereafter showed that huge portal hypertension was still present while more caval hypertension simultaneously appeared and aortic pressure rose to values of 80 mmH. These hemodynamic disturbances persisted until the end of the experiment. Contrarily, when BPC 157 was given in those circumstances of the portal and caval hypertension, and arterial hypotension, these disturbances were completely eliminated (Fig.1, *P≤0.05, at least vs. control). This may be a particularly therapeutic advantage. Namely, caval hypertension was consistently elevated in comparison to portal hypertension, with a gradient of at least 10 mmHg. Some spontaneous decompression of the portal system can be hardly expected by a portocaval shunt. Thereby, if not therapy, the pressure of both the portal and the caval system remains elevated after removal of the portal clamp. Discussion/Conclusion. Thus, the effectiveness of the one challenge given at distinctive points during reperfusion appears as the conclusive evidence. BPC 157 therapy distinctively mitigates the whole syndrome involving the course of an even more complex model that should include rats clamped by the hepatic artery, portal vein, and bile duct vs. rats that used to have a clamped portal triad and later underwent reperfusion

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA